Nucleix Announces Publication of Data on Methylation-Based Assay for Detecting High-Risk Non-Muscle Invasive Bladder Cancer in Journal of Clinical Pathology

Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder cancer population undergoing instillations

Study conducted at Agostino Gemelli University Hospital in Rome, Italy, shows it would be safe and effective to use Bladder EpiCheck to avoid unnecessary cystoscopies in high-risk patients.

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !